The methods include the amplification of DNA or RNA fusion polynucleotides from patient blood, tissue, or cells and the determination of a therapeutic regimen based on the presence of the fusion in the sample.
Read More
Proteins found in urine may enable diagnosis of Kawasaki disease.
Read More
CLP recently spoke with David Hout, PhD, VP of R&D, Insight Genetics, about continuing work on the Insight ALK Screen, Insight ALK Resistance, and other biomarker-specific diagnostic tools to advance cancer care.
Read More
Researchers have now developed and tested a promising new method for screening ALK fusions in NSCLC.
Read More
The test detects all types and all stages of lung cancer, including Stage I and II.
Read More